KEY POINTS
• miR-28 is a regulator of the Germinal Center reaction that dampens BCR signaling and impairs B cell proliferation and survival
• miR-28 has anti-tumoral activity in Burkitt and Diffuse Large B Cell lymphomas
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INTRODUCTION
Mature B cell lymphomas account for the vast majority of non-Hodgkin lymphomas (NHL), whose incidence has steadily increased over the past decades. Almost 400,000 new NHL cases are diagnosed and more than 200,000 people are estimated to die every year from NHL worldwide (data from Cancer Research UK). More than 60 percent of cases of mature B cell lymphomas are aggressive, fast growing subtypes and include diffuse large B cell lymphomas (DLBCL, 30% of all NHL) and Burkitt lymphoma/leukemia (BL, 2.5% of all NHL) 1 . While many aggressive B cell lymphomas can be cured with current therapies-most commonly doxorubicin-based combination chemotherapy with rituximab-these are highly intensive treatments, often requiring hospitalization. Moreover, almost half of DLBCL and BL cases are resistant to these approaches or relapse within 5 years of treatment . AID genotoxic activity provides one direct link between the GC reaction, the generation of lymphomagenic chromosome translocations and the propensity of mature B cells for oncogenic transformation [6] [7] [8] .
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B cell lymphomagenesis is also influenced by regulators of the GC gene expression program. Mice lacking the transcriptional repressor Bcl-6 are unable to form GCs or produce high affinity antibodies 10 and conversely, mice constitutively expressing in B cells develop a B cell malignancy that recapitulates DLBCL 11 . Lymphomagenesis is also promoted by transgenic overexpression of miR-155 and miR-217 12, 13 .
In recent years miRNA-based therapeutics for cancer treatment has stirred a lot of interest. miRNAs negatively regulate the expression of gene networks through imperfect base-pair binding to the 3'UTR of target mRNAs. Many human miRNAs are located in cancer-associated genomic regions 14 , and dysregulated miRNAs contribute, as oncogenes (oncomiRs) or tumor suppressors, to the tumorigenic process of numerous cancers, including lymphomas (reviewed in 15,16 and 17 ). These unique features of miRNAs may provide novel targets for anti-tumor therapy (reviewed in 18 and 19 ).
Here we have characterized miR-28, a GC-specific miRNA frequently lost during B cell transformation. Our results show that miR-28 regulates the GC reaction, hindering B 
METHODS

Expression constructs and transductions
miR-28 retroviral overexpression and sponge inhibition were performed as previously described 13, 51 , see supplemental data. For lentiviral constructs, the miR-28 precursor sequence was cloned into the pTRIPZ vector (Thermo scientific).
miR-28 detection by qRT-PCR
Total RNA was extracted with Trizol (Invitrogen) and miR-28-5p was measured by qRT-PCR using miR-28 miRCURY LNA primers (Exiqon). U6 amplification was used as a normalization control. Reactions were performed in a 7900HT fast real-time PCR thermocycler (Applied Biosystems).
RNA and iTRAQ analysis
Ramos cells transduced with miR-28 or scrambled pTRIPZ vectors were selected with puromycin (0.4μg/ml) and induced for 2 days with doxycycline (Dox) (0.5μg/ml); RFP + cells were isolated with a FACS Aria cell sorter and subjected to quantitative transcriptome and proteomic analysis (see supplementary Material and Methods).
RNAseq data accession number GSE81236. Proteomics data are deposited in PeptideAtlas and are accessible through the accession number PASS00874.
Lymphoma models
For subcutaneous xenografts, 2-10x10 6 Ramos cells were resuspended in 100 μL PBS, mixed with 100 μL Matrigel (BD Biosciences) and injected into NOD Scid Gamma (NSG) mice (8-14 weeks old). When transduced cells were used, Dox (Sigma-Aldritch) was administered at 0.04% in the drinking water. To establish subcutaneous λ -MYC primary tumors, enlarged lymph nodes were extracted from 4-to-8-month-old sick λ - 
RESULTS
miR-28 regulates the GC reaction
miR-28 is expressed in mouse and human GC B cells 20, 21 ; however, its role in the GC reaction remains unknown. We measured miR-28 expression by quantitative RT-PCR Figure S2 ). miR-28 was transduced along with red fluorescent protein (RFP) in a doxycycline inducible lentiviral vector, which promoted roughly a 40 fold increase of miR-28 levels, but did not affect the expression levels of other microRNAs ( Figure   S2B ). RFP + cells were subjected to RNAseq analysis for transcriptome profiling and to deep quantitative proteomics using multiplexed isobaric labeling (iTRAQ) (complete lists of products identified by RNAseq and iTRAQ can be found in Tables S1 and S2 ).
RNAseq analysis revealed that miR-28 induced expression changes in 1202 transcripts (p<0.05), 568 of which were downregulated ( Figure 2B ). We found a significant correlation between this group of downregulated mRNAs and those reported in a previous study for a different cell line 24 ( Figure S3 , thresholds log2FC<-0.4 or >+0.4).
In addition, GSEA 26 showed that computer-predicted miR-28 targets were significantly enriched in transcripts downregulated by miR-28 ( Figure 2C ) (p=0.004; NES=-1.42).
miR-28-induced downregulation was validated by qRT-PCR for CD44, CCDC50, CELSR3, VAV3, FOSB, and JAK3 ( Figure 2D ). iTRAQ analysis allowed quantification of more than 7.000 proteins, revealing miR-28-induced changes in 277
proteins (10% FDR, p<0.0038,), 171 of which were downregulated ( Figure 2B , right panel). Importantly, we found a consistent sign of expression change induced by miR-28 at the transcriptome and proteome levels (FDR <10% for proteins, p<0.05 for mRNAs, see Figure S4 for details).
Pathway enrichment analysis revealed that miR-28-induced transcriptome and proteome changes grouped in remarkably similar cellular function pathways ( Figure 2E ), and a class-scoring algorithm that identifies alterations in functional categories 27 showed that miR-28 expression in Ramos BL cells induces the coordinated downregulation of proteins belonging to cell cycle progression pathways ( Figure 2F ). Finally, Ingenuity
Pathway Analysis showed that proteins whose levels are altered by miR-28 form a
For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From highly significant cluster of genes involved in BCR signaling. This gene network contains four main hubs, BCR, PI3K, AKT, and ERK1/2, which play pivotal roles in B cell biology and regulate the induction of cell cycle and apoptosis regulatory molecules such as CDC6, CDC25C, TNFSF11 and ILF3 ( Figure 2G ). These results thus suggest that reintroducing miR-28 into lymphoma cells affects the signaling network emanating from the BCR.
miR-28 dampens BCR signaling and impairs B cell proliferation and survival
To assess the functional impact of miR-28 on BCR signaling, we quantified the Table 1 and Figure 3C ) and their expression correlated inversely with miR-28 expression in primary GC-derived lymphoma of the ABC DLBCL subtype (Fig 3D) ), which is known to specifically rely on chronic active BCR signaling for survival 28 . Overall, these results show that miR-28 expression downregulates downstream effectors of BCR signaling that play key roles in B lymphocyte proliferation and survival, and whose expression is frequently upregulated in GCderived malignancies.
To examine whether miR-28 expression regulates cell cycle and survival, we first 
miR-28 suppresses tumor growth in GC-derived neoplasms
To assess the tumor suppressor activity of miR-28 in vivo we first made use of Next, we assayed the anti-tumoral activity of a synthetic miR-28 mimic, an analog of the natural miRNA that is chemically modified to enhance stability and activity 29 . First, wild type Ramos BL cells were injected subcutaneously into NSG mice, tumors were allowed to reach a volume of 200 mm 3 , and mice were then given 3 intratumor mimic injections ( Figure S5C ). At both mimic doses and all time points analyzed, miR-28 mimic delayed the growth of established BL tumors ( Figure 5C-D) . We next tested the efficacy of miR-28 mimic when administered intravenously. Ramos BL xenografts were established as in the previous experiment, and mice were then given 2 intravenous intravenously injected with miR-28 mimic, and mice were sacrificed for analysis 3 days later ( Figure S5F ). The spleens of miR-28-treated mice were notably smaller than those treated with control mimic ( Figure 6G ) and contained a lower proportion of lymphoma B cells ( Figure 6H ). Indeed, intravenous miR-28 mimic reduced the proportion of B 
DISCUSSION
Our study addresses the role of miR-28 in the context of the GC and the establishment and maintenance of GC-derived neoplasms. Using miR-28 gain-of-function assays we found that miR-28 expression negatively regulates CSR and proliferation, whereas lossof-function miR-28 assays showed increased memory B and PC cell generation in vivo.
We hypothesize that miR-28-mediated regulation of cell proliferation and survival limits or terminates the GC reaction in vivo, thereby acting as a brake on B cell transformation. Supporting this idea, we detected progressively increasing miR-28 expression during the GC reaction and found that the loss of miR-28 expression is a frequent event in mature B cell neoplasms, both in man and mouse.
Although the mechanism regulating miR-28 expression in GCs remains to be determined, the lack of miR-28 upregulation in B cells stimulated in vitro ( 20 and our unpublished observations) hints at events linked to T-cell dependent stimulation in vivo.
Further research is merited into the events leading to miR-28 downregulation in a variety of B cell neoplasms, including CLL, DLBCL and BL; however, genomic loss and transcriptional regulation mechanisms are both likely to be important 24, 25 .
To identify the genes regulated by miR-28 in B cells we combined quantitative transcriptome and proteome analyses. We found a significant overlap between the mRNA targets found in our transcriptome analysis and those mRNAs showing the highest miR-28-induced fold changes in a previous report 24 . In our study, we considered that the combination of transcriptome and proteome approaches was the preferable choice for miRNA target identification, to allow the detection of miR-28 activity both at the level of mRNA stability reduction and at the level of translation inhibition 31, 32 . Importantly, this strategy has led to the finding that miR-28 significantly 25 suggests that ABC-DLBCL might be especially amenable to miR-28-based therapy.
Our miR-28 replacement experiments in a variety of in vivo lymphoma models confirm that miR-28 has anti-tumor activity. Our results show that prophylactic and therapeutic lentiviral delivery of miR-28 interferes with tumor establishment and growth both in BL and in DLBCL xenografts. These in vivo lymphoma models are widely used for preclinical anti-lymphoma drug testing 41 . In our work we have demonstrated that miR-
has anti-tumor activity not only in xenografts of human lymphoma cell lines, but also
For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From in different settings of murine primary lymphoma using λ-MYC mice, where B cell transformation is also linked to miR-28 loss. miR-28 re-expression impairs proliferation and survival pathways in lymphoma cells and suggests that the increased tumor cell death could be due to loss of Bcl-2, maybe by dampening BCR signaling. This hypothesis fits with the general idea that BCR signaling is central to the establishment and maintenance of GC-derived lymphomas 28, 36, 40, [42] [43] [44] [45] [46] . However, our profiling results are also compatible with contributions from other miR-28 targets regulating alternative pathways of proliferation and cell survival in lymphoma cells, or with NFκB and Bcl-2 being activated through signaling pathways alternative to the BCR.
In addition, we were also able to block lymphoma growth using synthetic mimics, which are thought to be the safest route for therapeutic miRNA reintroduction. In recent years the functional impact of miRNAs on cancer development has made them very attractive candidates for therapeutic strategies (reviewed in 47, 48 ). miRNAs potentially confer a high degree of specificity due to their intrinsic sequence-dependent target definition. Moreover, miRNAs target gene networks rather than individual genes, potentially making miRNA-based therapy less susceptible to the development of resistance. Finally, therapies based on replacing the normal levels of a tumor repressor miRNA that have been lost during tumorigenesis is expected to be significantly less toxic than anti-tumor treatments (reviewed in 18, 19 ). In line with the targeted nature of this approach, our data suggest that the toxicity of miR-28 will be considerably lower than current strategies for the treatment of B cell neoplasms.
From the therapeutic standpoint, it is important to identify drugs that can improve the efficacy and reduce the toxicity of standard anti-lymphoma therapy. This is particularly relevant for BL and DLBCL, which are often refractory to conventional chemotherapy 49, 50 . Taken together, the results of this study reveal the therapeutic potential of miR-28 
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